These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37228616)

  • 1. Cellular and transcriptional impacts of Janus kinase and/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis.
    Albeituni S; Oak N; Tillman HS; Stroh A; Keenan C; Bloom M; Nichols KE
    Front Immunol; 2023; 14():1137037. PubMed ID: 37228616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.
    Das R; Guan P; Sprague L; Verbist K; Tedrick P; An QA; Cheng C; Kurachi M; Levine R; Wherry EJ; Canna SW; Behrens EM; Nichols KE
    Blood; 2016 Mar; 127(13):1666-75. PubMed ID: 26825707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
    Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE
    Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis.
    Albeituni S; Verbist KC; Tedrick PE; Tillman H; Picarsic J; Bassett R; Nichols KE
    Blood; 2019 Jul; 134(2):147-159. PubMed ID: 31015190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFN-γ and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis.
    Humblet-Baron S; Franckaert D; Dooley J; Ailal F; Bousfiha A; Deswarte C; Oleaga-Quintas C; Casanova JL; Bustamante J; Liston A
    J Allergy Clin Immunol; 2019 Jun; 143(6):2215-2226.e7. PubMed ID: 30578871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis.
    Humblet-Baron S; Franckaert D; Dooley J; Bornschein S; Cauwe B; Schönefeldt S; Bossuyt X; Matthys P; Baron F; Wouters C; Liston A
    J Allergy Clin Immunol; 2016 Jul; 138(1):200-209.e8. PubMed ID: 26947179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-18 and cytotoxic impairment are independent and synergistic causes of murine virus-induced hyperinflammation.
    Tsoukas P; Rapp E; Van Der Kraak L; Weiss ES; Dang V; Schneider C; Klein E; Picarsic J; Salcedo R; Stewart CA; Canna SW
    Blood; 2020 Nov; 136(19):2162-2174. PubMed ID: 32589707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Deficiency of Interferon-γ Reveals Interferon-γ-Independent Manifestations of Murine Hemophagocytic Lymphohistiocytosis.
    Burn TN; Weaver L; Rood JE; Chu N; Bodansky A; Kreiger PA; Behrens EM
    Arthritis Rheumatol; 2020 Feb; 72(2):335-347. PubMed ID: 31400073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.
    Maschalidi S; Sepulveda FE; Garrigue A; Fischer A; de Saint Basile G
    Blood; 2016 Jul; 128(1):60-71. PubMed ID: 27222478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined IFN-γ and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice.
    Joly JA; Vallée A; Bourdin B; Bourbonnais S; Patey N; Gaboury L; Théorêt Y; Decaluwe H
    J Allergy Clin Immunol; 2023 Jan; 151(1):247-259.e7. PubMed ID: 35973477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice.
    Rothman JA; Das R; Teachey DT; Paessler ME; Nichols KE
    Pediatr Blood Cancer; 2011 Dec; 57(7):1239-43. PubMed ID: 21681935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice.
    Rood JE; Rao S; Paessler M; Kreiger PA; Chu N; Stelekati E; Wherry EJ; Behrens EM
    Blood; 2016 Jan; 127(4):426-35. PubMed ID: 26518437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
    Keenan C; Nichols KE; Albeituni S
    Front Immunol; 2021; 12():614704. PubMed ID: 33664745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations.
    Ghosh S; Carmo M; Calero-Garcia M; Ricciardelli I; Bustamante Ogando JC; Blundell MP; Schambach A; Ashton-Rickardt PG; Booth C; Ehl S; Lehmberg K; Thrasher AJ; Gaspar HB
    J Allergy Clin Immunol; 2018 Sep; 142(3):904-913.e3. PubMed ID: 29355678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale.
    Trantham T; Auten J; Muluneh B; Van Deventer H
    J Oncol Pharm Pract; 2020 Jun; 26(4):1005-1008. PubMed ID: 31575356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
    Meyer LK; Verbist KC; Albeituni S; Scull BP; Bassett RC; Stroh AN; Tillman H; Allen CE; Hermiston ML; Nichols KE
    Blood; 2020 Aug; 136(6):657-668. PubMed ID: 32530039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
    Hansen S; Alduaij W; Biggs CM; Belga S; Luecke K; Merkeley H; Chen LYC
    Eur J Haematol; 2021 May; 106(5):654-661. PubMed ID: 33523540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis.
    Jianguo L; Zhixuan Z; Rong L; Xiaodong S
    Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report.
    Sin JH; Zangardi ML
    Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):166-170. PubMed ID: 28834694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trigger-dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis.
    Gather R; Aichele P; Goos N; Rohr J; Pircher H; Kögl T; Zeiser R; Hengel H; Schmitt-Gräff A; Weaver C; Ehl S
    Eur J Immunol; 2020 Nov; 50(11):1770-1782. PubMed ID: 32419134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.